Lisata Therapeutics Inc. CEO David Mazzo provided an encouraging update on the company's Phase 1b/2a CENDIFOX trial, a clinical study evaluating the safety and efficacy of certepetide (formerly LSTA1) in combination with FOLFIRINOX-based therapies for pancreatic, colon, and appendiceal cancers.
Mazzo announced that Lisata has successfully completed patient enrollment for the pancreatic cancer cohorts in the trial, led by Dr. Anup Kasi at The University of Kansas Cancer Center. This milestone marks a significant step forward in the investigation of certepetide's potential as a treatment option for these challenging cancers.
Notably, the trial design allows for the collection of pre- and post-treatment biopsies of tumors, enabling researchers to gather valuable data on the drug's effects. Mazzo also highlighted ongoing efforts to complete enrollment in two additional cohorts focusing on colorectal cancer and other tumor types, with the goal of completing these cohorts by the end of the year.
Expressing his optimism, Mazzo noted the encouraging progress and enthusiasm surrounding the trial, which has attracted patients from the Kansas City area despite competition from other studies. He anticipates that preliminary results will be available by the end of the year, pending the timely processing of biopsies by external laboratories.
The CENDIFOX trial represents a significant step forward in the search for effective treatments for pancreatic and other challenging cancers. The completion of patient enrollment for the pancreatic cancer cohorts and the potential for preliminary results by year-end underscore the importance of this research and the promising progress being made by Lisata Therapeutics.
